Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Metagenomi (MGX) EBITDA Margin (2023 - 2025)

Metagenomi (MGX) has disclosed EBITDA Margin for 3 consecutive years, with 578.85% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 32581.0% to 578.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 350.33% through Dec 2025, down 20260.0% year-over-year, with the annual reading at 350.33% for FY2025, 20260.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 578.85% at Metagenomi, down from 235.52% in the prior quarter.
  • The five-year high for EBITDA Margin was 53.61% in Q2 2024, with the low at 608.84% in Q1 2025.
  • Average EBITDA Margin over 3 years is 246.32%, with a median of 206.55% recorded in 2023.
  • The sharpest move saw EBITDA Margin surged 6268bps in 2024, then crashed -38186bps in 2025.
  • Over 3 years, EBITDA Margin stood at 153.5% in 2023, then plummeted by -65bps to 253.05% in 2024, then tumbled by -129bps to 578.85% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 578.85%, 235.52%, and 236.78% for Q4 2025, Q3 2025, and Q2 2025 respectively.